Hansoh Pharma strikes 15B dollar Roche deal
Chinas Hansoh Pharmaceutical has agreed to a partnership and licensing deal with Roche potentially worth over 15 billion dollars. The agreement covers a portfolio of antibody-drug conjugate cancer programs and includes a 400 million dollar upfront payment.
Xurve View
Insights:
Xurve View
Hansoh Pharmaceutical Group struck a licensing agreement with Roche Holding AG-BR worth over $15 billion on Monday afternoon, covering antibody-drug conjugate programs.
